Edition:
United Kingdom

Profile: argenx SE (ARGX.BR)

ARGX.BR on Brussels Stock Exchange

121.30EUR
24 May 2019
Change (% chg)

-- (--)
Prev Close
€121.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
117,126
52-wk High
€122.40
52-wk Low
€54.30

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

Company Address

argenx SE

Willemstraat 5
BREDA     4811 AH
P: +3176.3030488

Company Web Links